Whole Genome Sequencing Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables, Services), By Type, By Workflow, By Application, By End-use, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global whole genome sequencing market size was exhibited at USD 1.85 billion in 2022 and is projected to hit around USD 11.54 billion by 2032, growing at a CAGR of 20.09% during the forecast period 2023 to 2032.

whole genome sequencing market size

Key Pointers:

  • The consumables segment dominated the market with the largest market share of 61.59% in 2022.
  • The services segment is expected to witness the fastest CAGR of 22.41% during the forecast period.
  • The large whole genome sequencing held the largest market share of 77.39% in 2022
  • The small whole genome sequencing segment is expected to witness the fastest growth at a CAGR of 22.25% during the forecast period.
  • The sequencing segment held the largest market share of 52.19% in 2022.
  • Data analysis is projected to witness the fastest growth with a CAGR of 21.38% during the forecast period.
  • The human whole genome sequencing segment dominated the market with the largest revenue share of 62.95% in 2022. 
  • The microbial whole genome sequencing market is expected to witness the fastest growth at a CAGR of 21.21% during 2023-2032.
  • The academic & research institutes segment held the largest market share of 48.75% in 2022.
  • Hospitals & clinics are projected to witness the fastest growth at a CAGR of 22.23% during the forecast period. 
  • North America held the largest market share of 51.39% in 2022
  • Asia Pacific region is anticipated to witness the fastest CAGR of 22.62% during the forecast period.

Whole Genome Sequencing Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 2.22 Billion

Market Size by 2032

USD 11.54 Billion

Growth Rate from 2023 to 2032

CAGR of 20.09%

Base year

2022

Forecast period

2023 to 2032

Segments covered

Product, Type, Workflow, Application, End-use

Regional scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key companies profiled

Illumina; Inc.; Thermo Fisher Scientific, Inc.; Oxford Nanopore Technologies; Pacific Biosciences of California, Inc.; BGI; QIAGEN; Agilent Technologies; ProPhase Labs Inc. (Nebula Genomics); Psomagen; Azenta US Inc.; (GENEWIZ)

 

The market growth can be attributed to the rising adoption of the whole genome sequencing for genome mapping programs and the increasing prevalence of inherited disorders, including rare genetic disorders. According to the study published in the New England Journal of Medicine in November 2021, whole genome sequencing could lead to the early diagnosis of a wide range of rare diseases and a reported transition to precision medicine.

Furthermore, the growing investment in R&D for the early detection and treatment of disorders with the aid of WGS is expected to propel the growth of the market. For instance, in February 2023, the government of Indonesia and the Genome Science Initiative, with the aid of USD 30 million investment from the Global Fund, established a network of facilities to perform the method for the early detection and treatment of disorders, including COVID-19, tuberculosis, cancer, genetic disorders, brain diseases, and metabolic disorders.

Whole genome sequencing has a wide range of applications, and government bodies are adopting these technologies for sequencing the genomes of humans, plant, animal, and microbes, which is expected to drive market growth. For instance, U.S. Food & Drug Administration (FDA) adopted the method to identify foodborne pathogens during foodborne disease outbreaks across the countries. The FDA has adopted this technology since 2008 under the Whole Genome Sequencing (WGS) program as it enables it to distinguish all strains of foodborne pathogens more efficiently than pulse-field gel electrophoresis (PFGE).

The rising technological advancements have led to the launch of innovative the whole genome sequencing products that offer an affordable, accurate, and timely diagnosis of various diseases and infections. This is contributing to the growth of the market. For instance, in December 2022, LifeCell International Pvt. Ltd. collaborated with HaystackAnalytics to launch ?TB, a whole genome sequencing test to identify the diagnostic information on tuberculosis infections and tackle the drug resistance challenge.

The COVID-19 pandemic led to an increased demand for the method globally, which enabled the rapid identification of SARS-CoV-2 and the development of possible diagnostic tests to manage the outbreak. Hence, governments across the globe collaborated with research organizations and the corporate sector to use the method to identify and diagnose SARS-CoV-2. Several companies have launched genomic services and rapid solutions for the surveillance of the SARS-CoV-2 virus. For instance, QIAGEN offers the whole genome sequencing services SARS-CoV-2 surveillance for the identification of potent mutants, tracing of possible outbreaks, and advancement of vaccine research and drug development.

Some of the prominent players in the Whole Genome Sequencing Market include:

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • BGI
  • QIAGEN
  • Agilent Technologies
  • ProPhase Labs, Inc. (Nebula Genomics)
  • Psomagen
  • Azenta US, Inc. (GENEWIZ)

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Whole Genome Sequencing market.

By Product 

  • Instruments
  • Consumables
  • Services

By Type 

  • Large Whole Genome Sequencing
  • Small Whole Genome Sequencing

By Workflow 

  • Pre-sequencing
  • Sequencing
  • Data Analysis

By Application 

  • Human Whole Genome Sequencing
  • Plant Whole Genome Sequencing
  • Animal Whole Genome Sequencing
  • Microbial Whole Genome Sequencing

By End-Use 

  • Academic & Research Institutes
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global whole genome sequencing market size was exhibited at USD 1.85 billion in 2022 and is projected to hit around USD 11.54 billion by 2032

The global whole genome sequencing market is expected to grow at a compound annual growth rate of 20.09% from 2023 to 2030

Some key players operating in the whole genome sequencing market include Illumina, Inc., Thermo Fisher Scientific, Inc., Oxford Nanopore Technologies, Pacific Biosciences of California, Inc., BGI, QIAGEN, Agilent Technologies, ProPhase Labs, Inc. (Nebula Genomics), Psomagen, Azenta US, Inc. (GENEWIZ)

Key factors that are driving the market growth include increasing healthcare expenditure globally, availability of advanced sequencing systems, increasing demand for next-generation sequencing technologies for genetic testing applications and others.

Chapter 1. Methodology and Scope
                   1.1. Information Procurement
                   1.2. Information or Data Analysis
                   1.3. Market Scope & Segment Definition
                   1.4. Market Model
                       1.4.1. Market Study, By Company Market Share
                       1.4.2. Regional Analysis
Chapter 2. Executive Summary
                   2.1. Market Snapshot
                   2.2. Segment Snapshot
                   2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                   3.1. Market Segmentation and Scope
                   3.2. Market Lineage Outlook
                       3.2.1. Parent Market Outlook
                       3.2.2. Related/Ancillary Market Outlook
                   3.3. Market Dynamics
                       3.3.1. Rising prevalence of inherited disorders
                       3.3.2. Decreasing costs for genetic sequencing
                       3.3.3. Rising demand for whole genome sequencing for genome mapping programs
                   3.4. Market Restraint Analysis
                       3.4.1. Ethical and legal challenges associated with genomic sequencing
                   3.5. Industry Analysis Tools
                       3.5.1. Porter's Five Forces Analysis
                       3.5.2. Macroeconomic Analysis
                   3.6. COVID-19 Impact Analysis
Chapter 4. Whole Genome Sequencing Market: Product Business Analysis
                   4.1. Whole Genome Sequencing Market: Product Market Share Analysis
                   4.2. Whole Genome Sequencing Market Estimates & Forecast, By Product
                   4.3. Instruments
                       4.3.1. Instruments Market, 2020 - 2032
                   4.4. Consumables
                       4.4.1. Consumables Market, 2020 - 2032
                   4.5. Services
                       4.5.1. Services Market, 2020 - 2032
Chapter 5. Whole Genome Sequencing Market: Type Business Analysis
                   5.1. Whole Genome Sequencing Market: Type Market Share Analysis
                   5.2. Whole Genome Sequencing Market Estimates & Forecast, By Type
                   5.3. Large Whole Genome Sequencing
                       5.3.1. Large Whole Genome Sequencing Market, 2020 - 2032
                   5.4. Small Whole Genome Sequencing
                       5.4.1. Small Whole Genome Sequencing Market, 2020 - 2032
Chapter 6. Whole Genome Sequencing Market: Workflow Business Analysis
                   6.1. Whole Genome Sequencing Market: Workflow Market Share Analysis
                   6.2. Whole Genome Sequencing Market Estimates & Forecast, By Workflow
                   6.3. Pre-Sequencing
                       6.3.1. Pre-Sequencing Market, 2020 - 2032
                   6.4. Sequencing
                       6.4.1. Sequencing Market, 2020 - 2032
                   6.5. Data Analysis
                       6.5.1. Data Analysis Market, 2020 - 2032
Chapter 7. Whole Genome Sequencing Market: Application Business Analysis
                   7.1. Whole Genome Sequencing Market: Application Market Share Analysis
                   7.2. Whole Genome Sequencing Market Estimates & Forecast, By Application
                   7.3. Human Whole Genome Sequencing
                       7.3.1. Human Whole Genome Sequencing Market, 2020 - 2032
                   7.4. Plant Whole Exome Sequencing
                       7.4.1. Plant Whole Exome Sequencing Market, 2020 - 2032
                   7.5. Animal Whole Exome Sequencing
                       7.5.1. Animal Whole Exome Sequencing Market, 2020 - 2032
                   7.6. Microbial Whole Exome Sequencing
                       7.6.1. Microbial Market, 2020 - 2032
Chapter 8. Whole Genome Sequencing Market: End-Use Business Analysis
                   8.1. Whole Genome Sequencing Market: End-Use Market Share Analysis
                   8.2. Whole Genome Sequencing Market Estimates & Forecast, By End-Use
                   8.3. Academic & Research Institutes
                       8.3.1. Academic & Research Institutes Market, 2020 - 2032
                   8.4. Hospitals & Clinics
                       8.4.1. Hospitals & Clinics Market, 2020 - 2032
                   8.5. Pharmaceutical & Biotechnology Companies
                       8.5.1. Pharmaceutical & Biotechnology Companies Market, 2020 - 2032
                   8.6. Others
                       8.6.1. Others Market, 2020 - 2032
Chapter 9. Whole Genome Sequencing Market: Regional Business Analysis
                   9.1. Whole Genome Sequencing Market Share By Region, 2023 & 2032
                   9.2. North America
                       9.2.1. North America Whole Genome Sequencing Market, 2020 - 2032
                       9.2.2. U.S.
                           9.2.2.1. Key Country Dynamics
                           9.2.2.2. Target Disease Prevalence
                           9.2.2.3. Competitive Scenario
                           9.2.2.4. Regulatory Framework
                           9.2.2.5. Reimbursement Scenario
                           9.2.2.6. U.S. Whole Genome Sequencing Market, 2020 - 2032
                       9.2.3. Canada
                           9.2.3.1. Key Country Dynamics
                           9.2.3.2. Target Disease Prevalence
                           9.2.3.3. Competitive Scenario
                           9.2.3.4. Regulatory Framework
                           9.2.3.5. Reimbursement Scenario
                           9.2.3.6. Canada Whole Genome Sequencing Market, 2020 - 2032
                   9.3. Europe
                       9.3.1. Europe Whole Genome Sequencing Market, 2020 - 2032
                       9.3.2. Germany
                           9.3.2.1. Key Country Dynamics
                           9.3.2.2. Target Disease Prevalence
                           9.3.2.3. Competitive Scenario
                           9.3.2.4. Regulatory Framework
                           9.3.2.5. Reimbursement Scenario
                           9.3.2.6. Germany Whole Genome Sequencing Market, 2020 - 2032
                       9.3.3. U.K.
                           9.3.3.1. Key Country Dynamics
                           9.3.3.2. Target Disease Prevalence
                           9.3.3.3. Competitive Scenario
                           9.3.3.4. Regulatory Framework
                           9.3.3.5. Reimbursement Scenario
                           9.3.3.6. U.K. Whole Genome Sequencing Market, 2020 - 2032
                       9.3.4. France
                           9.3.4.1. Key Country Dynamics
                           9.3.4.2. Target Disease Prevalence
                           9.3.4.3. Competitive Scenario
                           9.3.4.4. Regulatory Framework
                           9.3.4.5. Reimbursement Scenario
                           9.3.4.6. France Whole Genome Sequencing Market, 2020 - 2032
                       9.3.5. Italy
                           9.3.5.1. Key Country Dynamics
                           9.3.5.2. Target Disease Prevalence
                           9.3.5.3. Competitive Scenario
                           9.3.5.4. Regulatory Framework
                           9.3.5.5. Reimbursement Scenario
                           9.3.5.6. Italy Whole Genome Sequencing Market, 2020 - 2032
                       9.3.6. Spain
                           9.3.6.1. Key Country Dynamics
                           9.3.6.2. Target Disease Prevalence
                           9.3.6.3. Competitive Scenario
                           9.3.6.4. Regulatory Framework
                           9.3.6.5. Reimbursement Scenario
                           9.3.6.6. Spain Whole Genome Sequencing Market, 2020 - 2032
                       9.3.7. Denmark
                           9.3.7.1. Key Country Dynamics
                           9.3.7.2. Target Disease Prevalence
                           9.3.7.3. Competitive Scenario
                           9.3.7.4. Regulatory Framework
                           9.3.7.5. Reimbursement Scenario
                           9.3.7.6. Denmark Whole Genome Sequencing Market, 2020 - 2032
                       9.3.8. Sweden
                           9.3.8.1. Key Country Dynamics
                           9.3.8.2. Target Disease Prevalence
                           9.3.8.3. Competitive Scenario
                           9.3.8.4. Regulatory Framework
                           9.3.8.5. Reimbursement Scenario
                           9.3.8.6. Sweden Whole Genome Sequencing Market, 2020 - 2032
                       9.3.9. Norway
                           9.3.9.1. Key Country Dynamics
                           9.3.9.2. Target Disease Prevalence
                           9.3.9.3. Competitive Scenario
                           9.3.9.4. Regulatory Framework
                           9.3.9.5. Reimbursement Scenario
                           9.3.9.6. Norway Whole Genome Sequencing Market, 2020 - 2032
                   9.4. Asia Pacific
                       9.4.1. Asia Pacific Whole Genome Sequencing Market, 2020 - 2032
                       9.4.2. Japan
                           9.4.2.1. Key Country Dynamics
                           9.4.2.2. Target Disease Prevalence
                           9.4.2.3. Competitive Scenario
                           9.4.2.4. Regulatory Framework
                           9.4.2.5. Reimbursement Scenario
                           9.4.2.6. Japan Whole Genome Sequencing Market, 2020 - 2032
                       9.4.3. China
                           9.4.3.1. Key Country Dynamics
                           9.4.3.2. Target Disease Prevalence
                           9.4.3.3. Competitive Scenario
                           9.4.3.4. Regulatory Framework
                           9.4.3.5. Reimbursement Scenario
                           9.4.3.6. China Whole Genome Sequencing Market, 2020 - 2032
                       9.4.4. India
                           9.4.4.1. Key Country Dynamics
                           9.4.4.2. Target Disease Prevalence
                           9.4.4.3. Competitive Scenario
                           9.4.4.4. Regulatory Framework
                           9.4.4.5. Reimbursement Scenario
                           9.4.4.6. India Whole Genome Sequencing Market, 2020 - 2032
                       9.4.5. South Korea
                           9.4.5.1. Key Country Dynamics
                           9.4.5.2. Target Disease Prevalence
                           9.4.5.3. Competitive Scenario
                           9.4.5.4. Regulatory Framework
                           9.4.5.5. Reimbursement Scenario
                           9.4.5.6. South Korea Whole Genome Sequencing Market, 2020 - 2032
                       9.4.6. Australia
                           9.4.6.1. Key Country Dynamics
                           9.4.6.2. Target Disease Prevalence
                           9.4.6.3. Competitive Scenario
                           9.4.6.4. Regulatory Framework
                           9.4.6.5. Reimbursement Scenario
                           9.4.6.6. Australia Whole Genome Sequencing Market, 2020 - 2032
                       9.4.7. Thailand
                           9.4.7.1. Key Country Dynamics
                           9.4.7.2. Target Disease Prevalence
                           9.4.7.3. Competitive Scenario
                           9.4.7.4. Regulatory Framework
                           9.4.7.5. Reimbursement Scenario
                           9.4.7.6. Thailand Whole Genome Sequencing Market, 2020 - 2032
                   9.5. Latin America
                       9.5.1. Latin America Whole Genome Sequencing Market, 2020 - 2032
                       9.5.2. Brazil
                           9.5.2.1. Key Country Dynamics
                           9.5.2.2. Target Disease Prevalence
                           9.5.2.3. Competitive Scenario
                           9.5.2.4. Regulatory Framework
                           9.5.2.5. Reimbursement Scenario
                           9.5.2.6. Brazil Whole Genome Sequencing Market, 2020 - 2032
                       9.5.3. Mexico
                           9.5.3.1. Key Country Dynamics
                           9.5.3.2. Target Disease Prevalence
                           9.5.3.3. Competitive Scenario
                           9.5.3.4. Regulatory Framework
                           9.5.3.5. Reimbursement Scenario
                           9.5.3.6. Mexico Whole Genome Sequencing Market, 2020 - 2032
                       9.5.4. Argentina
                           9.5.4.1. Key Country Dynamics
                           9.5.4.2. Target Disease Prevalence
                           9.5.4.3. Competitive Scenario
                           9.5.4.4. Regulatory Framework
                           9.5.4.5. Reimbursement Scenario
                           9.5.4.6. Argentina Whole Genome Sequencing Market, 2020 - 2032
                   9.6. MEA
                       9.6.1. MEA Whole Genome Sequencing Market, 2020 - 2032
                       9.6.2. South Africa
                           9.6.2.1. Key Country Dynamics
                           9.6.2.2. Target Disease Prevalence
                           9.6.2.3. Competitive Scenario
                           9.6.2.4. Regulatory Framework
                           9.6.2.5. Reimbursement Scenario
                           9.6.2.6. South Africa Whole Genome Sequencing Market, 2020 - 2032
                       9.6.3. Saudi Arabia
                           9.6.3.1. Key Country Dynamics
                           9.6.3.2. Target Disease Prevalence
                           9.6.3.3. Competitive Scenario
                           9.6.3.4. Regulatory Framework
                           9.6.3.5. Reimbursement Scenario
                           9.6.3.6. Saudi Arabia Whole Genome Sequencing Market, 2020 - 2032
                       9.6.4. UAE
                           9.6.4.1. Key Country Dynamics
                           9.6.4.2. Target Disease Prevalence
                           9.6.4.3. Competitive Scenario
                           9.6.4.4. Regulatory Framework
                           9.6.4.5. Reimbursement Scenario
                           9.6.4.6. UAE Whole Genome Sequencing Market, 2020 - 2032
                       9.6.5. Kuwait
                           9.6.5.1. Key Country Dynamics
                           9.6.5.2. Target Disease Prevalence
                           9.6.5.3. Competitive Scenario
                           9.6.5.4. Regulatory Framework
                           9.6.5.5. Reimbursement Scenario
                           9.6.5.6. Kuwait Whole Genome Sequencing Market, 2020 - 2032
Chapter 10. Competitive Landscape
                   10.1. Company Categorization
                   10.2. Company Market Share Analysis, 2023
                   10.3. Strategy Mapping
                   10.4. Company Profiles/Listing
                       10.4.1. Illumina, Inc.
                           10.4.1.1. Overview
                           10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.1.3. Product Benchmarking
                           10.4.1.4. Strategic Initiatives
                       10.4.2. Thermo Fisher Scientific, Inc.
                           10.4.2.1. Overview
                           10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.2.3. Product Benchmarking
                           10.4.2.4. Strategic Initiatives
                       10.4.3. Oxford Nanopore Technologies
                           10.4.3.1. Overview
                           10.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.3.3. Product Benchmarking
                           10.4.3.4. Strategic Initiatives
                       10.4.4. Pacific Biosciences of California, Inc.
                           10.4.4.1. Overview
                           10.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.4.3. Product Benchmarking
                           10.4.4.4. Strategic Initiatives
                       10.4.5. BGI
                           10.4.5.1. Overview
                           10.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.5.3. Product Benchmarking
                           10.4.5.4. Strategic Initiatives
                       10.4.6. QIAGEN
                           10.4.6.1. Overview
                           10.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.6.3. Product Benchmarking
                           10.4.6.4. Strategic Initiatives
                       10.4.7. Agilent Technologies
                           10.4.7.1. Overview
                           10.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.7.3. Product Benchmarking
                           10.4.7.4. Strategic Initiatives
                       10.4.8. ProPhase Labs, Inc. (Nebula Genomics)
                           10.4.8.1. Overview
                           10.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.8.3. Product Benchmarking
                           10.4.8.4. Strategic Initiatives
                       10.4.9. Psomagen
                           10.4.9.1. Overview
                           10.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.9.3. Product Benchmarking
                           10.4.9.4. Strategic Initiatives
                       10.4.10. Azenta US, Inc. (GENEWIZ)
                           10.4.10.1. Overview
                           10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           10.4.10.3. Product Benchmarking
                           10.4.10.4. Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert